Literature DB >> 18564638

Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy.

V Soriano Gomis1, P Gonzalez Delgado, E Niveiro Hernandez.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18564638

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


× No keyword cloud information.
  7 in total

Review 1.  [Pharmacoprophylaxis and co-medications in allergen-specific immunotherapy].

Authors:  B Wedi; F Ruëff
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

2.  [Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab].

Authors:  D Wieczorek; A Kapp; B Wedi
Journal:  Hautarzt       Date:  2014-09       Impact factor: 0.751

3.  Combination of omalizumab and bee venom immunotherapy: does it work?

Authors:  İnsu Yılmaz; Sakine Nazik Bahçecioğlu; Murat Türk
Journal:  Asia Pac Allergy       Date:  2018-01-09

4.  Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab.

Authors:  Elisa Boni; Cristoforo Incorvaia; Marina Mauro
Journal:  Clin Mol Allergy       Date:  2016-10-24

Review 5.  Use of biologics in allergen immunotherapy.

Authors:  Wolfgang Pfützner; Mathias Schuppe
Journal:  Allergol Select       Date:  2021-02-19

6.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162

Review 7.  Anti-IgE Treatment for Disorders Other Than Asthma.

Authors:  Jeffrey Stokes
Journal:  Front Med (Lausanne)       Date:  2017-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.